BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 28127652)

  • 1. The Impact of Pathologically Positive Lymph Nodes in the Clinically Negative Neck: An Analysis of 39,301 Patients with Papillary Thyroid Cancer.
    Ruel E; Thomas S; Perkins JM; Roman SA; Sosa JA
    Ann Surg Oncol; 2017 Jul; 24(7):1935-1942. PubMed ID: 28127652
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Knowledge of pathologically versus clinically negative lymph nodes is associated with reduced use of radioactive iodine post-thyroidectomy for low-risk papillary thyroid cancer.
    Ruel E; Thomas S; Dinan MA; Perkins JM; Roman SA; Sosa JA
    Endocrine; 2016 Jun; 52(3):579-86. PubMed ID: 26708045
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Central Lymph Node Status has Significant Prognostic Value in the Clinically Node-Negative Tall-Cell Variant of Papillary Thyroid Cancer Regardless of T-Staging and Radioactive Iodine Administration: First Evidence From a Population-Based Study.
    Shi X; Huang NS; Lei BW; Song KH; Shi RL; Wei WJ; Hu WP; Dong F; Wang Y; Wang YL; Ji QH
    Ann Surg Oncol; 2018 Aug; 25(8):2316-2322. PubMed ID: 29845406
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk Factors for Central Neck Lymph Node Metastases in Micro- Versus Macro- Clinically Node Negative Papillary Thyroid Carcinoma.
    Sessa L; Lombardi CP; De Crea C; Tempera SE; Bellantone R; Raffaelli M
    World J Surg; 2018 Mar; 42(3):623-629. PubMed ID: 29238850
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical response to radioactive iodine therapy for prophylactic central neck dissection is not superior to total thyroidectomy alone in cN0 patients with papillary thyroid cancer.
    Lin B; Qiang W; Wenqi Z; Tianyu Y; Lina Z; Bin J
    Nucl Med Commun; 2017 Dec; 38(12):1036-1040. PubMed ID: 28953211
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Practice patterns among thyroid cancer surgeons: implications of performing a prophylactic central neck dissection.
    Deutschmann MW; Chin-Lenn L; Nakoneshny SC; Dort JC; Pasieka JL; Chandarana SP
    J Otolaryngol Head Neck Surg; 2016 Oct; 45(1):55. PubMed ID: 27793192
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of Survival Outcomes Following Postsurgical Radioactive Iodine Versus External Beam Radiation in Stage IV Differentiated Thyroid Carcinoma.
    Yang Z; Flores J; Katz S; Nathan CA; Mehta V
    Thyroid; 2017 Jul; 27(7):944-952. PubMed ID: 28446057
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The prognostic value of the metastatic lymph node ratio and maximal metastatic tumor size in pathological N1a papillary thyroid carcinoma.
    Jeon MJ; Yoon JH; Han JM; Yim JH; Hong SJ; Song DE; Ryu JS; Kim TY; Shong YK; Kim WB
    Eur J Endocrinol; 2013 Feb; 168(2):219-25. PubMed ID: 23161752
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The impact of socioeconomic status on the use of adjuvant radioactive iodine for papillary thyroid cancer.
    Zevallos JP; Xu L; Yiu Y
    Thyroid; 2014 Apr; 24(4):758-63. PubMed ID: 24378070
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-Dose RAI Therapy Justified by Pathological N1a Disease Revealed by Prophylactic Central Neck Dissection for cN0 Papillary Thyroid Cancer Patients: Is it Superior to Low-Dose RAI Therapy?
    Wei L; Bai L; Zhao L; Yu T; Ma Q; Ji B
    World J Surg; 2019 May; 43(5):1256-1263. PubMed ID: 30684002
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TIMING OF RADIOACTIVE IODINE THERAPY DOES NOT IMPACT OVERALL SURVIVAL IN HIGH-RISK PAPILLARY THYROID CARCINOMA.
    Suman P; Wang CH; Abadin SS; Block R; Raghavan V; Moo-Young TA; Prinz RA; Winchester DJ
    Endocr Pract; 2016 Jul; 22(7):822-31. PubMed ID: 27018620
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical impact of radioactive iodine dose selection based on the number of metastatic lymph nodes in patients with papillary thyroid carcinoma: A multicenter retrospective cohort study.
    Kwon SY; Kim MH; Kong E; Chong A; Yoo SW; Jeon S; Park SA; Kim DW; Kang SH; Choi JE; Ha JM; Jeong SY; Lee SW
    Clin Endocrinol (Oxf); 2021 Dec; 95(6):901-908. PubMed ID: 34185324
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk factors for recurrence of papillary thyroid carcinoma with clinically node-positive lateral neck.
    Lee CW; Roh JL; Gong G; Cho KJ; Choi SH; Nam SY; Kim SY
    Ann Surg Oncol; 2015 Jan; 22(1):117-24. PubMed ID: 25034816
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Undetectable thyroglobulin after total thyroidectomy in patients with low- and intermediate-risk papillary thyroid cancer--is there a need for radioactive iodine therapy?
    Ibrahimpasic T; Nixon IJ; Palmer FL; Whitcher MM; Tuttle RM; Shaha A; Patel SG; Shah JP; Ganly I
    Surgery; 2012 Dec; 152(6):1096-105. PubMed ID: 23158181
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Timing of Adjuvant Radioactive Iodine Therapy Does Not Affect Overall Survival in Low- and Intermediate-Risk Papillary Thyroid Carcinoma.
    Suman P; Wang CH; Moo-Young TA; Prinz RA; Winchester DJ
    Am Surg; 2016 Sep; 82(9):807-14. PubMed ID: 27670568
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk Factors for Lateral Neck Recurrence of N0/N1a Papillary Thyroid Cancer.
    Kim Y; Roh JL; Gong G; Cho KJ; Choi SH; Nam SY; Kim SY
    Ann Surg Oncol; 2017 Nov; 24(12):3609-3616. PubMed ID: 28822118
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Radioactive iodine ablation may not decrease the risk of recurrence in intermediate-risk papillary thyroid carcinoma.
    Kim SK; Woo JW; Lee JH; Park I; Choe JH; Kim JH; Kim JS
    Endocr Relat Cancer; 2016 May; 23(5):367-76. PubMed ID: 26917553
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical outcome of patients with papillary thyroid carcinoma who have recurrence after initial radioactive iodine therapy.
    Vassilopoulou-Sellin R; Schultz PN; Haynie TP
    Cancer; 1996 Aug; 78(3):493-501. PubMed ID: 8697396
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lateral Neck Lymph Node Characteristics Prognostic of Outcome in Patients with Clinically Evident N1b Papillary Thyroid Cancer.
    Wang LY; Palmer FL; Nixon IJ; Tuttle RM; Shah JP; Patel SG; Shaha AR; Ganly I
    Ann Surg Oncol; 2015 Oct; 22(11):3530-6. PubMed ID: 25665952
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Excellent Prognosis of Central Lymph Node Recurrence-Free Survival for cN0M0 Papillary Thyroid Carcinoma Patients Who Underwent Routine Prophylactic Central Node Dissection.
    Ito Y; Miyauchi A; Masuoka H; Fukushima M; Kihara M; Miya A
    World J Surg; 2018 Aug; 42(8):2462-2468. PubMed ID: 29372373
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.